7 Analysts Have This To Say About Amgen
Portfolio Pulse from Benzinga Insights
Analyst ratings for Amgen (NASDAQ:AMGN) show varied opinions over the last quarter, with recent actions including maintaining, raising, and lowering ratings and price targets. The average 12-month price target for AMGN has increased to $328.57, up 7.73% from $305.00. Amgen's financial performance shows solid revenue growth but challenges in net margin and asset utilization. The company's debt-to-equity ratio is higher than the industry average, indicating a reliance on borrowed funds.
April 03, 2024 | 3:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Analyst ratings for Amgen have shown a mix of opinions, with recent adjustments in ratings and price targets. The average 12-month price target has increased, indicating a positive outlook. However, financial challenges such as lower net margin and asset utilization, along with a high debt-to-equity ratio, may impact investor sentiment.
The increase in the average 12-month price target suggests a positive short-term outlook for AMGN, likely to influence investor sentiment positively. However, the financial challenges highlighted, such as lower net margin and high debt-to-equity ratio, could temper optimism and impact the stock's performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100